A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923

Clinical Breast Cancer
A HamiltonM Piccart

Abstract

This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer.

References

Aug 18, 1994·Nature·L A Feig, B Schaffhausen
Jun 1, 1994·International Journal of Cancer. Journal International Du Cancer·D P Lane
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F RevillionJ P Peyrat
Nov 15, 1996·Cell·T F Gajewski, C B Thompson
Feb 21, 1997·Science·P Golstein
May 29, 1997·International Journal of Cancer. Journal International Du Cancer·S C LinnG Giaccone
Mar 12, 1998·International Journal of Cancer. Journal International Du Cancer·S RozanX Sastre-Garau
Sep 25, 1998·Journal of the National Cancer Institute·A D ThorE T Liu

❮ Previous
Next ❯

Citations

Jan 23, 2008·American Journal of Clinical Pathology·David G Hicks, Swati Kulkarni
Mar 20, 2002·Clinical Breast Cancer·C Lohrisch, M Piccart
Aug 24, 2013·The Breast : Official Journal of the European Society of Mastology·B K LinderholmT Hatschek
Oct 27, 2004·Critical Reviews in Oncology/hematology·Anis Feki, Irmgard Irminger-Finger
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela MoliterniGianni Bonadonna
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine Van PoznakAndrew D Seidman
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathleen I PritchardBindi Dhesy-Thind
Aug 25, 2006·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hitoshi Tsuda
Feb 6, 2004·Molecular & Cellular Proteomics : MCP·Jeffrey S RossGabriel N Hortobagyi
Feb 8, 2007·International Journal of Cancer. Journal International Du Cancer·Stefania TommasiAngelo Paradiso
Jul 20, 2007·Breast Cancer Research and Treatment·Bindi Dhesy-ThindMaureen Trudeau
Dec 10, 2009·Nature Reviews. Clinical Oncology·Philippe L BedardMartine J Piccart-Gebhart
Aug 5, 2003·The Oncologist·Jeffrey S RossKenneth J Bloom
Apr 15, 2008·New Zealand Veterinary Journal·J S MundayR A Squires
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·France DocquierElena Klenova
Jun 26, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles DumontetJohn C Reed
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seung Jin KimShinzaburo Noguchi
Mar 26, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nikola I Valkov, Daniel M Sullivan
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AnelliF Soares
Jul 1, 2021·World Journal of Clinical Oncology·Alejandro EspañolMaría Elena Sales
Jul 22, 2008·Clinical Breast Cancer·Shou-Ching Tang

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.